A detailed history of Guggenheim Capital LLC transactions in Axonics, Inc. stock. As of the latest transaction made, Guggenheim Capital LLC holds 28,398 shares of AXNX stock, worth $2.02 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
28,398
Previous 40,485 29.86%
Holding current value
$2.02 Million
Previous $2.72 Million 27.31%
% of portfolio
0.01%
Previous 0.02%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$67.3 - $69.67 $813,455 - $842,101
-12,087 Reduced 29.86%
28,398 $1.98 Million
Q2 2024

Aug 14, 2024

SELL
$66.47 - $69.65 $20,805 - $21,800
-313 Reduced 0.77%
40,485 $2.72 Million
Q1 2024

May 14, 2024

SELL
$56.67 - $69.36 $1.24 Million - $1.52 Million
-21,950 Reduced 34.98%
40,798 $2.81 Million
Q4 2023

Feb 14, 2024

SELL
$49.38 - $63.75 $14,221 - $18,360
-288 Reduced 0.46%
62,748 $3.9 Million
Q3 2023

Nov 14, 2023

BUY
$48.64 - $62.51 $512,519 - $658,667
10,537 Added 20.07%
63,036 $3.54 Million
Q2 2023

Aug 11, 2023

BUY
$47.99 - $60.21 $120,838 - $151,608
2,518 Added 5.04%
52,499 $2.65 Million
Q1 2023

May 10, 2023

BUY
$52.6 - $67.34 $363,623 - $465,521
6,913 Added 16.05%
49,981 $2.73 Million
Q4 2022

Feb 14, 2023

SELL
$59.56 - $76.6 $98,988 - $127,309
-1,662 Reduced 3.72%
43,068 $2.69 Million
Q3 2022

Nov 14, 2022

BUY
$57.96 - $78.12 $840,362 - $1.13 Million
14,499 Added 47.96%
44,730 $3.15 Million
Q2 2022

Aug 15, 2022

BUY
$39.5 - $64.42 $179,646 - $292,982
4,548 Added 17.71%
30,231 $1.71 Million
Q1 2022

May 16, 2022

BUY
$43.74 - $62.76 $1.12 Million - $1.61 Million
25,683 New
25,683 $1.61 Million

Others Institutions Holding AXNX

About Axonics, Inc.


  • Ticker AXNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 49,123,600
  • Market Cap $3.49B
  • Description
  • Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention...
More about AXNX
Track This Portfolio

Track Guggenheim Capital LLC Portfolio

Follow Guggenheim Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Guggenheim Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Guggenheim Capital LLC with notifications on news.